A permanent reimbursement code for YUTIQ, an implant intended to treat chronic eye inflammation made by EyePoint Pharmaceuticals, was assigned by CMS one quarter early.
Three details:
1. The code, J7314, will become effective Oct. 1 , earlier than the usually scheduled time at the beginning of the upcoming year.
2. In the past, CMS issued J-codes for reimbursement yearly, but now releases them quarterly.
3. "YUTIQ reimbursement is currently being processed through the utilization of either a miscellaneous or a shared billing code, and payer support for reimbursement of YUTIQ has been positive. The Oct. 1 effective date of a permanent J-code specific to YUTIQ will allow treating physicians, insurers and patients to benefit sooner from a more streamlined approval and reimbursement process,” said Nancy Lurker, president and CEO of EyePoint Pharmaceuticals.